

## Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 5

**Date:** 30/08/2022

**Location:** Hybrid meeting – NICE Office, 2 Redman Place and via Zoom

**Minutes:** Confirmed

<b>Committee members present:</b>	
Alison Cameron (Chair)	(Present for notes 1 – 8)
Ranjit Manchanda (Topic Advisor)	(Present for notes 1 – 8)
Victoria Barber	(Present for notes 1 – 8)
Adam Brentnall	(Present for notes 1 – 8)
Rebecca Bowen	(Present for notes 1 – 8)
Melanie Davies (Virtually AM, in person PM)	(Present for notes 1 – 8)
Gareth Evans	(Present for notes 1 – 8)
Glenn McCluggage	(Present for notes 1 – 8)
Tracie Miles	(Present for notes 1 – 8)
Davina Moses	(Present for notes 1 – 8)
Fiona Robb (virtually)	(Present for notes 1 – 8)
Adam Rosenthal	(Present for notes 2 – 8)
Vishakha Tripathi	(Present for notes 1 – 8)
Britta Stordal	(Present for notes 1 – 8)

<b>In attendance:</b>		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Suhayl Kassam (virtually)	Systematic Reviewer	(Present for notes 1 – 8)
Katriona O'Donoghue	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Emma Clegg	Information Scientist	(Present for notes 1 – 8)
Nick Staples	Guideline Commissioning Manager	(Present for notes 1 – 8)
<b>Apologies:</b>		
Judith Hayward	Committee member (GP)	

Joanne Stanford	Committee member (Lay)
Lucy Side	Committee member
Laura Berg	Systematic Reviewer
Neil Ryan	Clinical Fellow
Hayley Shaw	Project Manager
Steve Pilling	Clinical Advisor

### **1. Welcome, housekeeping, aims of the day and apologies**

The Chair welcomed the committee members and attendees to the 5<sup>th</sup> meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk and outlined the hybrid meeting etiquette.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives and the hybrid meeting etiquette.

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair asked everyone to verbally declare any interests that have risen since the last meeting.

It was confirmed that the declared interest and any interests declared previously did not prevent attendees from fully participating in the meeting. The declared interest was an update on an already existing interest about a study they are involved in which has now started.

### **3. Minutes of the last meeting**

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

### **4. Morning presentations**

The Chair introduced Katharina Dworzynski, Guideline Lead who gave a presentation on NICE processes related to research recommendations.

Eric Slade, Senior Health Economist, gave an update on economic modelling on surveillance.

The Chair introduced Nathan Bromham, Senior Systematic Reviewer, who presented evidence review questions 3.1: What are the optimal methods of assessing the probability of having a pathogenic variant associated with familial ovarian cancer? and 3.2: What are the optimal methods of assessing the absolute risk of ovarian cancer in women at increased risk of ovarian cancer?

### **5. Lay member forum**

Lay members were given the opportunity to reflect and make any suggestions or

comments to the other committee members.

## **6. Afternoon presentations**

Nathan Bromham, Senior Systematic Reviewer, continued leading the committee through evidence review questions 3.1 and 3.2.

The Chair introduced Suhayl Kassam, Systematic Reviewer, who presented the protocol for review question: 1.1: What information and support is needed by women with familial ovarian cancer or who are at increased risk of ovarian cancer (with or without breast cancer), and their families and carers?

Nathan Bromham, Senior Systematic Reviewer, presented the protocol for review question 7.1 How effective are preventive medicines for reducing the incidence of ovarian cancer for women at increased risk of familial ovarian cancer?

## **7. Questions and discussion**

The committee discussed:

- NICE processes for research recommendations
- Economic modelling on surveillance update
- Review questions 3.1 and 3.2
- The protocol for review questions 1.1 and 7.1

## **8. Any other business and summary of actions**

Katharina Dworzynski summarised the actions set at the meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

**Date of next meeting:** 13/10/2022

**Location of next meeting:** Virtually via zoom.